Academic literature on the topic 'Pain Treatment Queensland Townsville'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Contents
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pain Treatment Queensland Townsville.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Pain Treatment Queensland Townsville"
1
Sabesan, Sabe, Clare Senko, Andrew Schmidt, Abhishek Joshi, Ritwik Pandey, Corinne A. Ryan, Megan Lyle, et al. "Enhancing Chemotherapy Capabilities in Rural Hospitals: Implementation of a Telechemotherapy Model (QReCS) in North Queensland, Australia." Journal of Oncology Practice 14, no. 7 (July 2018): e429-e437. http://dx.doi.org/10.1200/jop.18.00110.
Full textAbstract:
Introduction: The Queensland Remote Chemotherapy Supervision (QReCS) model enables rural nurses to administer chemotherapy in smaller rural towns under supervision by health professionals from larger centers using telehealth. Its implementation began in North Queensland, Australia (population, 650,000), in 2014 between two regional cancer centers (Townsville and Cairns as primary sites) and six rural sites (125 to 1,000 kilometers from primary sites). Our study examined the implementation processes, feasibility, and safety of this model. Methods: Details of implementation and patients’ clinical details for the period of 2014 to 2016 for descriptive analysis were extracted from telechemotherapy project notes and oncology information systems of North Queensland, respectively. Results: After a successful pilot study in Townsville Cancer Centre, statewide rural and cancer networks of Queensland Health, in collaboration with clinicians and managers across the state of Queensland, developed the QReCS model and a guide for operationalizing it. QReCS was implemented at six sites from 2014 to 2016. Main enablers across North Queensland included collaboration among clinicians and managers, availability of common electronic medical records, funding from Queensland Health, and installation of telehealth infrastructure by statewide telehealth services. Main barriers included turnover of senior management and nursing staff at two rural towns. Sixty-two patients received 327 cycles of low- to medium-risk chemotherapy agents. Rates of treatment delays, adverse events, and hospital admissions were similar to those in face-to-face care. Conclusion: Implementation of the QReCS model across a large geographic region is feasible with acceptable safety profiles. Leadership by and collaboration among clinicians and managers, adequacy of resources and common governance are key enablers.
2
Fletcher, James, Sebastian Kang, Amy Brown, Sabe S. Sabesan, Megan Lyle, Ritwik Pandey, Andrew Lui, et al. "Administration of immune checkpoint inhibitors using teleoncology model of care in Far North Queensland: A multicenter review of safety outcomes." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): 2084. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.2084.
Full textAbstract:
2084 Background: The Teleoncology model of care, as developed and implemented across health services in Far North Queensland (Australia), improves access to specialist oncology services, including telehealth supervised administration of Oncology drugs for patients in rural/remote towns. There is limited published data regarding the safety of checkpoint inhibitor immunotherapy when it is administered via Teleoncology. Aim: Evaluate safety of immunotherapy administration via Teleoncology, including immune-related adverse events (irAE), treatment delays, hospital admissions and interhospital transfers, in comparison to a retrospective control population. Methods: Retrospective review of all patients treated with immunotherapy via Teleoncology as part of Cairns and Hinterland Hospital and Health Service (CHHHS) and the Townsville Teleoncology Network (TTN) between January 2015 and April 2019. A retrospective cohort treated at Townsville Cancer Centre over the same time period was used as a control group. Results: Fifty-one patients received a total of 624 cycles of immunotherapy (all single agent anti-PD-1/L-1) via Teleoncology. The control population included 142 patients who received 1697 cycles of immunotherapy. Baseline characteristics were well matched between groups. Compared to the control population, patients treated via telehealth did not have statistically significant differences in the rate of Grade 3+ irAE (13.7% v 8%), hospital admissions (13.7% v 7.4%) or protocol suspensions due to immune toxicity (16% v 10%). One patient with Grade 3+ irAE required interhospital transfer for investigation and management, which occurred within 24 hours of presentation to hospital. There were no treatment-related mortalities in either group. Conclusions: Checkpoint inhibitor immunotherapy can safely be delivered using the Teleoncology model of care in rural and remote centres. The incidence of toxicity for single agent immunotherapy was predictably low and not significantly different between groups, however the numbers in this retrospective study were small. The time to recognition and management of immune mediated toxicity in rural and remote centres is an important factor that was not assessed in this study and will be considered in future work.
3
Sabesan, S. S., B. Burgher, S. Varma, and P. Piliouras. "Perception and knowledge of clinical trials and factors affecting participation of regional and rural cancer patients of North Queensland." Journal of Clinical Oncology 27, no. 15_suppl (May 20, 2009): e17558-e17558. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.e17558.
Full textAbstract:
e17558 Background: The best treatment option for most cancers is participation in clinical trials. Participation in trials is generally low and among rural patients it is likely to be even lower. The aim of this study was to assess knowledge about and attitudes towards clinical trials among rural and regional cancer patients of North Queensland. Methods: A questionnaire-based survey was conducted in outpatient clinics at the Townsville Cancer Centre on all types of cancer patients. Results: The mean age of the 178 participants was 56 years and 45.4% lived in rural or remote areas. Median distance to the trial centre (Townsville) for rural participants was 180 km (range 80 - 1300 km). Being asked whether they would take part in a RCT, 13.2% of participants said no, 56.3% said yes, and 30.5% were unsure. There were no significant relationships between willingness to participate and rurality (p = 0.896) or education level (p = 0.943). For the majority of patients, the number of clinic visits and blood tests required did not matter. Cost of travel (41.1% rural/remote; 23.5% regional; p < 0.001) and the need for family or friends to accompany (38.9% rural/remote; 24.1% regional; p = 0.021) were more important for rural/remote than regional patients as factors affecting participation. Only 16.4% of participants were aware of early studies. After education, percentage of patients willing to participate in phase I and II studies were 57% and 84%, respectively. Rural patients were less willing to participate in phase I studies than regional patients (33.9% vs 52.6%, p = 0.029). Conclusions: Rural patients are as interested in participating in clinical trials as urban patients except for phase 1 trials and should not be excluded because of rurality. Knowledge of trials is poor and there is a need for education early. Cost of travel seems more important for rural patients and as such budgets should include cost of travel to encourage participation of rural patients. No significant financial relationships to disclose.
4
Buhrer-Skinner, Monika, Reinhold Muller, Petra G. Buettner, Rose Gordon, and Joseph Debattista. "Improving Chlamydia trachomatis retesting rates by mailed self-collection kit." Sexual Health 8, no. 2 (2011): 248. http://dx.doi.org/10.1071/sh10064.
Full textAbstract:
Background To assess a mailed self-collection kit for chlamydia testing as an intervention to increase post-treatment retesting rates. Methods: This prospective intervention study took place at a sexual health clinic in Townsville, North Queensland (Australia) between 2006 and 2008. The intervention consisted of offering to mail a self-collection kit for retesting 3 months after treatment. The achieved retesting rates were compared to those from the previous year and to concurrent controls who did not participate in the intervention. Both control groups received standard advice on retesting. Results: Of the 46 participants in the intervention group, 34.8% returned the sample for retesting 3 to 4 months after initial treatment, in comparison to 6.8% of the historic control groups (n = 206) and 1.4% of the concurrent control group (n = 142) (P < 0.001, respectively). Conclusions: Retesting rates for Chlamydia trachomatis were substantially and significantly improved using the mailed self-collection kit evidencing that the kit could deliver a much needed intervention to improve notoriously low retesting rates.
5
Ward, Kayla, Anirudh Krishnan, Krishnan R Iyengar, Thomas Robertson, Richard White, and Ravindra Urkude. "Haycocknema perplexum myositis: the first description of subclinical disease and a proposed distinctive triad to evoke clinical suspicion." BMJ Neurology Open 4, no. 1 (May 2022): e000290. http://dx.doi.org/10.1136/bmjno-2022-000290.
Full textAbstract:
IntroductionHaycocknema perplexum is an exceedingly rare cause of parasitic myositis endemic to Australia, more specifically, Tasmania and North Queensland. There is a paucity of literature regarding this diagnosis, with only nine previously described cases.DiagnosisThis report details two cases of biopsy-confirmed H. perplexum myositis from Townsville University Hospital and describes the first-ever case of subclinical infection. There is limited known information regarding the H. perplexum life cycle and a definitive host which has hindered the development of a non-invasive diagnostic test. A review of the previously described cases has identified the hallmark features of this enigmatic condition: a triad of serological markers including deranged hepatic function, persistent eosinophilia and an elevated creatine kinase.ConclusionsThis report aimed to raise awareness of H. perplexum myositis and the possibility of subclinical infection, which suggests a protracted disease course. Further research is required to identify a non-invasive diagnostic test, given that early diagnosis and timely initiation of albendazole treatment may drastically limit patient disability.
6
O’Dwyer, Niamh, Harrison Cliffe, Kaitlyn E. Watson, Elizabeth McCourt, and Judith A. Singleton. "The Forgotten Patients in Cyclones: The Continuation of Opioid Replacement Therapy Program." Prehospital and Disaster Medicine 34, s1 (May 2019): s53. http://dx.doi.org/10.1017/s1049023x19001237.
Full textAbstract:
Introduction:Cyclones are expected to increase in frequency and intensity, significantly impacting communities and healthcare services. During these times, those with chronic diseases such as opioid dependence are at an increased risk of disease exacerbation due to treatment regimen interruptions. Disruptions to the continuity of the opioid replacement therapy (ORT) service can be detrimental to both clients and the community which can potentially lead to relapse, withdrawal, and risky behaviors.Aim:To explore the impacts of cyclones on opioid treatment programs within community and hospital pharmacies in Queensland.Methods:Qualitative research methods were used in this study with two methods of data analysis employed: the text analytics software, Leximancer®, and manual coding. Interviews were conducted with five hospital and five community pharmacists and four Queensland opioid treatment program (QOTP) employees. Participants worked in Mackay, Rockhampton, Townsville, and Yeppoon in a community impacted by a cyclone and involved with ORT supply.Results:The themes developed in the manual coding were “impact on essential services,” “human experience,” “healthcare infrastructure,” “preparedness,” and “interprofessional networks.” These themes were aligned with those identified in the Leximancer® analysis. The community pharmacists focused on client stability, whereas, the hospital pharmacists and QOTP employees focused on the need for disaster plans to be implemented.Discussion:The greatest concern for participants was maintaining the stability of their clients. Communication amongst the dosing sites and ORT stakeholders was most concerning. This led to a lack of dosing information in a timely manner with pharmacists being hesitant to provide doses and takeaways due to legislative restrictions. A review of coordinated efforts and the legislative constraints is recommended to ensure continuity of ORT supply during cyclones.
7
McGrath, Pam. "Treatment for childhood acutelymphoblastic leukaemia:the fathers' perspective." Australian Health Review 24, no. 2 (2001): 135. http://dx.doi.org/10.1071/ah010135.
Full textAbstract:
Research on parental adaptation to a child's chronic illness is still scant, and this is particularly so in relation to theexperience of treatment for paediatric Acute Lymphoblastic Leukaemia (ALL). The work that does exist on parentalreactions tends to conflate maternal responses with paternal responses, as fathers are usually seen as having a secondaryrole. Consequently, little is known about how fathers cope with treatment for childhood ALL. The present discussionseeks to make a contribution to this area by presenting findings on the paternal experience of treatment for paediatricALL from a longitudinal study conducted at Royal Children's Hospital in Brisbane, Queensland. The findings fromthis research clearly indicate the emotional pain that fathers face in their struggle to accept the diagnosis of a serious,life-threatening illness such as ALL in their child. The findings challenge the notion of the male stereotype by showingthat the shock of diagnosis, the emotional pain of coping with the illness, the expression of pain through tears, thedesire to be with the child, the struggle to cope with the medical interventions, and concerns about other familymembers are not gender specific, but are rather issues common to both parents.
8
Buhrer-Skinner, Monika, Reinhold Muller, Arun Menon, and Rose Gordon. "Novel approach to an effective community-based chlamydia screening program within the routine operation of a primary healthcare service." Sexual Health 6, no. 1 (2009): 51. http://dx.doi.org/10.1071/sh08019.
Full textAbstract:
Background: A prospective study was undertaken to develop an evidence-based outreach chlamydia screening program and to assess the viability and efficiency of this complementary approach to chlamydia testing within the routine operations of a primary healthcare service. Methods: A primary healthcare service based in Townsville, Queensland, Australia, identified high-prevalence groups for chlamydia in the community. Subsequently, a series of outreach clinics were established and conducted between August 2004 and November 2005 at a defence force unit, a university, high school leavers’ festivities, a high school catering for Indigenous students, youth service programs, and backpacker accommodations. Results: All target groups were easily accessible and yielded high participation. Chlamydia prevalence ranged between 5 and 15% for five of the six groups; high school leavers had no chlamydia. All participants were notified of their results and all positive cases were treated (median treatment interval 7 days). Five of the six assessed groups were identified as viable for screening and form the basis for the ongoing outreach chlamydia screening program. Conclusion: The present study developed an evidence-based outreach chlamydia screening program and demonstrated its viability as a complementary approach to chlamydia testing within the routine operations of the primary healthcare service, i.e. without the need for additional funding. It contributes to the evidence base necessary for a viable and efficient chlamydia management program. Although the presented particulars may not be directly transferable to other communities or health systems, the general two-step approach of identifying local high-risk populations and then collaborating with community groups to access these populations is.
9
Khalili, Ellie, Brent Venning, Mike Boggild, and Simon A. Broadley. "082 Real world experience of treating multiple sclerosis with alemtuzumab." Journal of Neurology, Neurosurgery & Psychiatry 89, no. 6 (May 24, 2018): A33.2—A33. http://dx.doi.org/10.1136/jnnp-2018-anzan.81.
Full textAbstract:
IntroductionAlemtuzumab is a highly effective therapy for multiple sclerosis that has a significant, but well-defined adverse event profile. We report cases treated since the commercial release of alemtuzumab at two centres in Queensland with the aim of comparing real-world experience with trial data.MethodsThis was a retrospective case note review of patients treated with alemtuzumab for multiple sclerosis since becoming commercially available in Australia. The two sites were the Gold Coast University Hospital and the Townsville Hospital. Demographic, clinical and MRI data were systematically collected from the available records at each site. De-identified aggregated data were analysed using descriptive statistics (mean (±SD), median (range)) and compared with phase III clinical trial data.Results104 cases treated with alemtuzumab were identified at the two sites. The median age at first treatment was 3817–55 years, slightly older than the trial populations (33 and 35 years) and two-thirds were female. The mean disease duration was 8.4 (±7.0) years, which is longer that seen in the trials (2.1 and 4.5 years). The median number of prior relapses was 31–12 with 1 (0–3) in the prior 2 years. The median number of prior treatments for MS was 1.5. The median follow up was 201–35 months. The median EDSS at time of first treatment was 2 (0–7) and at last follow up was 1.5 (0–7). At last follow up, 24/104 (23%) had improved, 61/104 (58%) were stable and 9/104 (9%) had worsened. Autoimmune adverse events were seen in 18/104 (17%) with autoimmune thyroid disease being the most common (13/104 (13%).ConclusionAlemtuzumab is an effective therapy for MS. Clinical outcomes in a real world setting were similar to those seen in phase III clinical trials. Autoimmune diseases occurred in a similar proportion to those seen in clinical trials.References. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: A randomised controlled phase 3 trial. Lancet2012;380(9856):1819–28.. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012;380(9856):1829–39.
10
Day, Melissa A., L. Charles Ward, Dawn M. Ehde, Beverly E. Thorn, John Burns, Amanda Barnier, Jason B. Mattingley, and Mark P. Jensen. "A Pilot Randomized Controlled Trial Comparing Mindfulness Meditation, Cognitive Therapy, and Mindfulness-Based Cognitive Therapy for Chronic Low Back Pain." Pain Medicine 20, no. 11 (January 3, 2019): 2134–48. http://dx.doi.org/10.1093/pm/pny273.
Full textAbstract:
AbstractObjectiveThis pilot trial compared the feasibility, tolerability, acceptability, and effects of group-delivered mindfulness meditation (MM), cognitive therapy (CT), and mindfulness-based cognitive therapy (MBCT) for chronic low back pain (CLBP).SettingUniversity of Queensland Psychology Clinic.SubjectsParticipants were N = 69 (intent-to-treat [ITT] sample) adults with CLBP.DesignA pilot, assessor-blinded randomized controlled trial.MethodsParticipants were randomized to treatments. The primary outcome was pain interference; secondary outcomes were pain intensity, physical function, depression, and opioid medication use. The primary study end point was post-treatment; maintenance of gains was evaluated at three- and six-month follow-up.ResultsRatings of acceptability, and ratios of dropout and attendance showed that MBCT was acceptable, feasible, and well tolerated, with similar results found across conditions. For the ITT sample, large improvements in post-treatment scores for pain interference, pain intensity, physical function, and depression were found (P < 0.001), with no significant between-group differences. Analysis of the follow-up data (N = 43), however, revealed that MBCT participants improved significantly more than MM participants on pain interference, physical function, and depression. The CT group improved more than MM in physical function. The MBCT and CT groups did not differ significantly on any measures.ConclusionsThis is the first study to examine MBCT for CLBP management. The findings show that MBCT is a feasible, tolerable, acceptable, and potentially efficacious treatment option for CLBP. Further, MBCT, and possibly CT, could have sustained benefits that exceed MM on some important CLBP outcomes. A future definitive randomized controlled trial is needed to evaluate these treatments and their differences.
Dissertations / Theses on the topic "Pain Treatment Queensland Townsville"
1
Yelland, Michael John. "Randomised controlled trial of prolotherapy injections, saline injections and exercises in the treatment of chronic low back pain /." [St. Lucia, Qld.], 2005. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18660.pdf.
Full text
2
Paungmali, Aatit. "An investigation of a neuro-biological mechanism of a mobilisation-with-movement treatment /." St. Lucia, Qld, 2004. http://www.library.uq.edu.au/pdfserve.php?image=thesisabs/absthe18040.pdf.
Full text
3
Smith, Sarah. "A study into osteopathic treatment of pregnant women in NSW and Queensland." Thesis, 2005. https://vuir.vu.edu.au/890/.
Full textAbstract:
Throughout pregnancy, the body undergoes continual musculoskeletal changes, which can be frequently associated with functional limitations and disability such as pelvic pain and low back pain, however, there is little literature regarding the role of the osteopathic profession in the treatment of the pregnant patient. The osteopath has the opportunity to contribute to the musculoskeletal system structure and function and hence influence the altered homeostasis hence reducing the patients discomfort and making the pregnancy more comfortable for the woman.
This study aims to determine treatment modalities utilized by osteopaths for treatment of pregnant patient, and the rate and incorporation of patient education as part of the management of the pregnant women in NSW and Queensland. This study has highlighted that the majority of sample osteopaths surveyed treat pregnant women using similar techniques, that they don't only treat the musculoskeletal system but also provide information and support throughout the pregnancy. It has shown that the sample practitioners feel their qualifications in the field are underestimated, illustrating that the profession needs to educate not only the public but also fellow primary health care practitioners, so they are more aware of the role Osteopaths could play in the treatment of pregnant women in the future.
This minor thesis was written by a post-graduate student as part of the requirements of the Master of Health Science (Osteopathy) program.